Beta blockers in traumatic brain injury: a systematic review and meta-analysis
Trauma Surgery & Acute Care Open · 2023-03 · 8 (1) · e001051
DOI: 10.1136/tsaco-2022-001051 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Trauma Surgery & Acute Care Open, online erschienen am 02.03.2023. Verfasst von Shannon Hart und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurosurgery, Hamilton Health Sciences, Hamilton, Ontario, Canada. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Traumatic brain injury (TBI) is a major cause of death and disability worldwide. Beta blockers have shown promise in improving mortality and functional outcomes after TBI. The aim of this article is to synthesize the available clinical data on the use of beta blockers in acute TBI.
Methods
A systematic search was conducted through MEDLINE, Embase, and Cochrane Central Register of Controlled Trials for studies including one or more outcomes of interest associated with use of beta blockers in TBI. Independent reviewers evaluated the quality of the studies and extracted data on all patients receiving beta blockers during their hospital stay compared with placebo or non-intervention. Pooled estimates, CIs, and risk ratios (RRs) or ORs were calculated for all outcomes.
Results
13 244 patients from 17 studies were eligible for analysis. Pooled analysis demonstrated a significant mortality benefit of overall use of beta blocker (RR 0.8, 95% CI 0.68 to 0.94, I 2 =75%). Subgroup analysis of patients with no preinjury use of beta blocker compared with patients on preinjury beta blockers showed no mortality difference (RR 0.99, 95% CI 0.7 to 1.39, I 2 =84%). There was no difference in rate of good functional outcome at hospital discharge (OR 0.94, 95% CI 0.56 to 1.58, I 2 =65%); however, there was a functional benefit at longer-term follow-up (OR 1.75, 95% CI 1.09 to 2.8, I 2 =0%). Cardiopulmonary and infectious complications were more likely in patients who received beta blockers (RR 1.94, 95% CI 1.69 to 2.24, I 2 =0%; RR 2.36, 95% CI 1.42 to 3.91, I 2 =88%). Overall quality of the evidence was very low.
Conclusions
Use of beta blockers is associated with decreased mortality at acute care discharge as well as improved functional outcome at long-term follow-up. Lack of high-quality evidence limits definitive recommendations for use of beta blockers in TBI; therefore, high-quality randomized trials are needed to further elucidate the utility of beta blockers in TBI. PROSPERO registration number CRD42021279700.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Neurosurgery, Hamilton Health Sciences, Hamilton, Ontario, Canada.
- Faculty of Medicine, McMaster University, Hamilton, Ontario, Canada.
- Departments of Surgery and Critical Care, Hamilton Health Sciences, Hamilton, Ontario, Canada.
ORCID-Profile: Shannon Hart, Andrew Chen
Zitieren
APA
Hart, S., Lannon, M., Chen, A., Martyniuk, A., Sharma, S., & Engels, P. T. (2023). Beta blockers in traumatic brain injury: a systematic review and meta-analysis. Trauma Surgery & Acute Care Open, 8(1), e001051. https://doi.org/10.1136/tsaco-2022-001051
Vancouver
Hart S, Lannon M, Chen A, Martyniuk A, Sharma S, Engels PT. Beta blockers in traumatic brain injury: a systematic review and meta-analysis. Trauma Surgery & Acute Care Open. 2023;8(1):e001051. doi:10.1136/tsaco-2022-001051
BibTeX
@article{Hart2023,
author = {Hart, Shannon and Lannon, Melissa and Chen, Andrew and Martyniuk, Amanda and Sharma, Sunjay and Engels, Paul T},
title = {Beta blockers in traumatic brain injury: a systematic review and meta-analysis},
journal = {Trauma Surgery & Acute Care Open},
year = {2023},
volume = {8},
number = {1},
pages = {e001051},
doi = {10.1136/tsaco-2022-001051}
}
EUVIMED